<DOC>
	<DOC>NCT00733876</DOC>
	<brief_summary>The purpose of this trial is to determine if the administration of allogeneic MSCs at defined doses is safe in patients who are at high risk of developing significant Acute Kidney Injury (AKI) after undergoing on-pump cardiac surgery.</brief_summary>
	<brief_title>Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Kidney Tubular Necrosis, Acute</mesh_term>
	<criteria>Documented ischemic coronary heart and/or valvular heart disease:Acceptable candidate for elective CABG and/or Cardiac Valve Surgery Patients at high risk for postop AKI:Age 18 or older if at high risk for postop AKI because of underlying Diabetes mellitus (type I or II), CHF, COPD Chronic Kidney Disease (CKD) stage 14 Patients at high risk for postop AKI :age &gt; 65 or combinations Patent femoral artery without aortic aneurysm Ability to give informed consent. Presence of ongoing local or systemic infection Younger than 18 Participation in another clinical trial Pregnancy Contraindication to general anesthesia Prisoner Dialysis patient (CKD6) or patient with CKD5 History of malignancy except nonmelanoma skin cancer Occluded Groin arteries Uncontrolled Diabetes mellitus (HbA1c &gt; 10, history of diabetic ketoacidosis or osmolar coma within the last three months) Nonhealing foot ulcers. Clinical evidence of severe peripheral vascular disease (ABI &lt; 0.3) Coronary Angiogram &lt; 7 days before surgery Inadequate preoperative time to obtain baseline kidney function data due to urgent/emergent surgery Unstable myocardium (evolving myocardial infarction), cardiogenic shock</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Acute Renal Failure Cardiac Surgery Stem Cell</keyword>
</DOC>